Pages Menu
TwitterRssFacebook
Categories Menu

Posted by on Jun 29, 2013 in Medical Journals |

Histamine and ascorbic acid in human blood.

Head for The Masto Townhall forum to debate this paper.This article may be copyrighted. Notice to copyright holders. You can view the full article at the publisher here. This article can be downloaded for free
J Nutr. 1980 Apr;110(4):662-8.

Histamine and ascorbic acid in human blood.

Clemetson CA.

Abstract

Analysis of 437 human blood samples has shown that when the plasma-reduced ascorbic acid level falls below 1 mg/100 ml, the whole blood histamine level increases exponentially as the ascorbic acid level decreases. When the ascorbic acid level falls below 0.7 mg/100 ml, there is a highly significant increase in the blood histamine level. Oral administration of ascorbic acid (1 g daily for 3 days) to 11 selected volunteers resulted in a reduction of the blood histamine level in every instance.

PMID: 7365537 [PubMed – indexed for MEDLINE]

Read More

Posted by on Jun 14, 2013 in Medical Journals |

Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
This is a free article and no fee is due to download it.
Cytometry B Clin Cytom. 2011 Nov;80(6):362-8. doi: 10.1002/cyto.b.20606. Epub 2011 Jun 8.

Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.

Perbellini O, Zamò A, Colarossi S, Zampieri F, Zoppi F, Bonadonna P, Schena D, Artuso A, Martinelli G, Chilosi M, Pizzolo G, Zanotti R.

Abstract

BACKGROUND:

According to the World Health Organization (WHO) classification the diagnosis of systemic mastocytosis (SM) relies on bone marrow (BM) examination and is based on one major and four minor criteria. Herein, we used WHO criteria to compare flow cytometry (FC) with other available techniques in the diagnosis of SM after BM examination.

METHODS:

We analyzed a cohort of 95 patients with suspect SM. All patients underwent comprehensive BM examination by using cytology, immunohistochemistry, FC and molecular study for mutation of c-Kit and serum tryptase dosage. FC evaluation was based on a combination of monoclonal antibodies, specifically CD25/CD2/CD45/CD34/CD117.

RESULTS:

Seventy-four out of ninety-five patients were diagnosed with indolent SM (n = 59) or monoclonal mast cell activation syndrome (n = 15) because satisfying less than 3 minor criteria. Thirty-nine out of these seventy-four patients fulfilled the major histological criterion, whereas the presence of a minor criterion was assessed by FC, molecular study, cytology, and tryptase level in 70/74, 52/67, 56/74, and 42/74 patients, respectively. FC showed higher sensitivity than IHC in detection of CD25+ mast cells (MC) (92.9% vs. 73.8%; P = 0.019), especially in the absence of the major histological criterion (90.5% vs. 47.6%; P = 0.003). Moreover, CD2 expression was documented by FC and IHC in 97.1% and 35.3% of cases, respectively (P < 0.001).

CONCLUSIONS:

FC showed the best sensitivity for identifying abnormal MC compared to other techniques, especially in cases with low MC burden. Therefore, we hope for a major role of FC in the diagnostic work-up of clonal MC disorders.

2011 International Clinical Cytometry Society.

PMID: 21656905 [PubMed – indexed for MEDLINE] Free full text
Read More

Posted by on Jun 14, 2013 in Medical Journals |

Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
There is a fee associated with downloading this article.
Allergy. 2011 Feb;66(2):229-37. doi: 10.1111/j.1398-9995.2010.02477.x. Epub 2010 Sep 7.

Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis.

Niedoszytko M, Oude Elberink JN, Bruinenberg M, Nedoszytko B, de Monchy JG, te Meerman GJ, Weersma RK, Mulder AB, Jassem E, van Doormaal JJ.

Abstract

BACKGROUND:

  Mastocytosis is an uncommon disease resulting from proliferation of abnormal mast cells infiltrating skin, bone marrow, liver, and other tissues. The aim of this study was to find differences in gene expression in peripheral blood cells of patients with indolent systemic mastocytosis compared to healthy controls. The second aim was to define a specific gene expression profile in patients with mastocytosis.

METHODS:

  Twenty-two patients with indolent systemic mastocytosis and 43 healthy controls were studied. Whole genome gene expression analysis was performed on RNA samples isolated from the peripheral blood. For amplification and labelling of the RNA, the Illumina TotalPrep 96 RNA Amplification Kit was used. Human HT-12_V3_expression arrays were processed. Data analysis was performed using GeneSpring, Genecodis, and Transcriptional System Regulators.

RESULTS:

  Comparison of gene expression between patients and controls revealed a significant difference (P < 0.05 corrected for multiple testing) and the fold change difference >2 in gene expression in 2303 of the 48.794 analysed transcripts. Functional annotation indicated that the main pathways in which the differently expressed genes were involved are ubiquitin-mediated proteolysis, MAPK signalling pathway, pathways in cancer, and Jak-STAT signalling. The expression distributions for both groups did not overlap at all, indicating that many genes are highly differentially expressed in both groups.

CONCLUSION:

  We were able to find abnormalities in gene expression in peripheral blood cells of patients with indolent systemic mastocytosis and to construct a gene expression profile which may be useful in clinical practice to predict the presence of mastocytosis and in further research of novel drugs.

© 2010 John Wiley & Sons A/S.

PMID: 21208217 [PubMed – indexed for MEDLINE]
Read More

Posted by on Jun 14, 2013 in Medical Journals |

Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
There is a fee associated with downloading this article.
Allergy. 2011 May;66(5):648-57. doi: 10.1111/j.1398-9995.2010.02521.x. Epub 2010 Dec 8.

Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis.

Niedoszytko M, Bruinenberg M, van Doormaal JJ, de Monchy JG, Nedoszytko B, Koppelman GH, Nawijn MC, Wijmenga C, Jassem E, Elberink JN.

Abstract

BACKGROUND:

Anaphylaxis to insect venom (Hymenoptera) is most severe in patients with mastocytosis and may even lead to death. However, not all patients with mastocytosis suffer from anaphylaxis. The aim of the study was to analyze differences in gene expression between patients with indolent systemic mastocytosis (ISM) and a history of insect venom anaphylaxis (IVA) compared to those patients without a history of anaphylaxis, and to determine the predictive use of gene expression profiling.

METHODS:

Whole-genome gene expression analysis was performed in peripheral blood cells.

RESULTS:

Twenty-two adults with ISM were included: 12 with a history of IVA and 10 without a history of anaphylaxis of any kind. Significant differences in single gene expression corrected for multiple testing were found for 104 transcripts (P < 0.05). Gene ontology analysis revealed that the differentially expressed genes were involved in pathways responsible for the development of cancer and focal and cell adhesion suggesting that the expression of genes related to the differentiation state of cells is higher in patients with a history of anaphylaxis. Based on the gene expression profiles, a naïve Bayes prediction model was built identifying patients with IVA.

CONCLUSIONS:

In ISM, gene expression profiles are different between patients with a history of IVA and those without. These findings might reflect a more pronounced mast cells dysfunction in patients without a history of anaphylaxis. Gene expression profiling might be a useful tool to predict the risk of anaphylaxis on insect venom in patients with ISM. Prospective studies are needed to substantiate any conclusions.

© 2010 John Wiley & Sons A/S.

PMID: 21143240 [PubMed – indexed for MEDLINE]
Read More

Posted by on Jun 14, 2013 in Medical Journals |

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
This is a free article and no fee is due to download it.
PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375. Epub 2011 Oct 21.

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.

Abstract

Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288) and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a database with Hamilton scores using Principal Component Analysis (PCA). Efficacy of masitinib therapy was evaluated using non parametric Wilcoxon test for paired data within a three months period (n = 35). Our results show that patients with indolent mastocytosis present an elevated prevalence of depression (64%). Depression was moderate in 56% but severe in 8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests) characterized depression in mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases) of overall depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms.

PMID: 22031830 [PubMed – indexed for MEDLINE] PMCID: PMC3198767 Free PMC Article
Read More

Posted by on Jun 14, 2013 in Medical Journals |

Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
This is a free article and no fee is due to download it.
Intern Med. 2011;50(6):611-5. Epub 2011 Mar 15.

Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.

Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J.

Abstract

We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.

PMID: 21422688 [PubMed – indexed for MEDLINE] Free full text
Read More